Browsing Tag
DLL3
3 posts
Is DLL3 becoming the most strategic biomarker target in neuroendocrine oncology?
Can dual DLL3 targeting improve SCLC outcomes? Read PDN’s deep analysis of the Boehringer Ingelheim and Zai Lab collaboration today.
Is this the most promising DLL3-targeting therapy yet? Zai Lab advances ADC into Phase 3
Zai Lab’s DLL3-targeting ADC for small cell lung cancer shows high brain metastasis activity; global Phase 3 trial now underway. Explore the data and future impact.
Innovent Biologics and Roche partner to advance DLL3 antibody drug conjugate
Innovent Biologics, Inc., a biopharmaceutical company, has entered a strategic global licensing agreement with Roche to propel the…